Unopposed estrogen increases total plasma factor VII, but not active factor VII: A short-term placebo-controlled study of healthy postmenopausal women

Thrombosis and Haemostasis

Volumn 84, Issue 6, 2000, Pages 968-972

  De Valk De Roo, G W ^a   Stehouwer, C D A ^a   Emeis, J J ^a   Nicolaas Merkus, A ^a   Netelenbos, C ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Estrogen; Factor VII; Postmenopausal; Postprandial

Indexed keywords

BLOOD CLOTTING FACTOR 7; ESTRADIOL; ESTROGEN;

ADULT; ARTICLE; BLOOD CLOTTING PARAMETERS; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FAT INTAKE; FEMALE; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0034536415     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614157     Document Type: Article

References (34)

1. Hormone replacement therapy, heart disease, and other considerations
2. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women
3. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque
4. Interleukin-1 activation of vascular endothelium. Effects on procoagulant activity and leukocyte adhesion
5. The endotoxin-induced coagulant activity of human monocytes
6. Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells
7. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
8. Coagulation factor VII and the risk of coronary heart disease in healthy men
9. Prospective study of hemostatic factors and incidence of coronary heart disease: The Atherosclerosis Risk in Communities (ARIC) Study
10. Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII
11. The effect of hormone replacement therapy of the age-related rise of factor VIIc, and its activity state
12. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators
13. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation
14. Factor VIIa response to a fat-rich meal does not depend on fatty acid composition. A randomized controlled trial
15. Postprandial elevation of activated factor VII in young adults
16. In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway
17. Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency
18. Postprandial lipaemia and haemostatic factors
19. Prospective study of exogeneous hormones and risk of pulmonary embolism in women
20. Risk of venous thromboembolism in users of hormone replacement therapy
21. Coronary Drug Project Research Group - Initial findings leading to modifications of its research protocol
22. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial
23. Transdermal estrogen replacement therapy: Beneficial effects on hemostatic risk factors for cardiovascular disease
24. The effect of two regimens of hormone replacement therapy on the haemostatic profile in postmenopausal women
25. The writing group for the estradiol clotting factors study. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: A 1-year, double-blind, placebo-controlled study
26. Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women
27. The effects of transdermal oestradiol and oral progestogens on haemostasis variables
28. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy
29. Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: A 2-year, placebo-controlled study
30. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables
31. A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters
32. Contribution of factor VII genotype to activated FVII levels. Differences in genotype frequencies between northern and southern European populations
33. Genetic determination of coagulation factor VIIc levels among healthy middle-aged women
34. Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration